Brian D Williamson
Overview
Explore the profile of Brian D Williamson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen P, Lambson B, Mkhize N, Moodley C, Yssel A, Moyo-Gwete T, et al.
J Virol
. 2025 Jan;
99(2):e0173024.
PMID: 39817771
The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against...
2.
Importance of variables from different time frames for predicting self-harm using health system data
Wolock C, Williamson B, Shortreed S, Simon G, Coleman K, Yeargans R, et al.
J Biomed Inform
. 2024 Nov;
160:104750.
PMID: 39557209
Objective: Self-harm risk prediction models developed using health system data (electronic health records and insurance claims information) often use patient information from up to several years prior to the index...
3.
Importance of variables from different time frames for predicting self-harm using health system data
Wolock C, Williamson B, Shortreed S, Simon G, Coleman K, Yeargans R, et al.
medRxiv
. 2024 Oct;
PMID: 39371167
Objective: Self-harm risk prediction models developed using health system data (electronic health records and insurance claims information) often use patient information from up to several years prior to the index...
4.
Williamson B, Wu L, Huang Y, Hudson A, B Gilbert P
PLoS One
. 2024 Sep;
19(9):e0310042.
PMID: 39240995
Combination monoclonal broadly neutralizing antibodies (bnAbs) are currently being developed for preventing HIV-1 acquisition. Recent work has focused on predicting in vitro neutralization potency of both individual bnAbs and combination...
5.
Navarro S, Williamson B, Huang Y, Gowda G, Raftery D, Tinker L, et al.
Metabolites
. 2024 Aug;
14(8).
PMID: 39195559
Metabolomics has been used extensively to capture the exposome. We investigated whether prospectively measured metabolites provided predictive power beyond well-established risk factors among 758 women with adjudicated cancers [ =...
6.
Phelan E, Williamson B, Balderson B, Cook A, Piccorelli A, Fujii M, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2424234.
PMID: 39052289
Importance: High-risk medications that contribute to adverse health outcomes are frequently prescribed to older adults. Deprescribing interventions reduce their use, but studies are often not designed to examine effects on...
7.
Carrell D, Floyd J, Gruber S, Hazlehurst B, Heagerty P, Nelson J, et al.
J Am Med Inform Assoc
. 2024 May;
31(8):1785-1796.
PMID: 38748991
Objective: To present a general framework providing high-level guidance to developers of computable algorithms for identifying patients with specific clinical conditions (phenotypes) through a variety of approaches, including but not...
8.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Nat Commun
. 2024 Mar;
15(1):2175.
PMID: 38467646
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine...
9.
Williamson B, Huang Y
Int J Biostat
. 2024 Feb;
20(2):347-359.
PMID: 38348882
In many applications, it is of interest to identify a parsimonious set of features, or panel, from multiple candidates that achieves a desired level of performance in predicting a response....
10.
Juraska M, Bai H, deCamp A, Magaret C, Li L, Gillespie K, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(4):e2308942121.
PMID: 38241441
In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition...